AASLD/IDSA 2025 Hepatitis B Guideline Shifts From Guidance to Recommendations
The first formal AASLD/IDSA HBV guideline (versus prior guidance) tightens antiviral treatment thresholds, adds tenofovir alafenamide for pregnancy, and newly addresses horizontal transmission and expanded liver cancer surveillance.
AASLD/IDSA 2025 Hepatitis B Practice GuidelineAmerican Association for the Study of Liver DiseasesInfectious Diseases Society of Americachronic hepatitis Bnucleos(t)ide analoguestenofovir alafenamidetenofovir disoproxil fumaratehepatocellular carcinoma surveillanceInfectious Disease / Antimicrobials
Background Information
New guidelines reshape hepatitis B virus management strategies.
Updated guidelines provide critical information on the management of hepatitis B virus (HBV), affecting treatment decisions and patient outcomes. The guidelines emphasize new evidence in antiviral therapy selection, monitoring strategies, and treatment initiation criteria. Clinicians must familiarize themselves with these guideline updates to optimize HBV management and improve patient care outcomes. Stay updated with the latest HBV management guidelines to ensure best practices in patient treatment.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.